Standing on the brink of a technological revolution in medicine, the National Center for Gene Therapy and Drugs Based on RNA Technology today unites 44 organizations—including universities, research institutions, and private companies—under a shared goal of transforming scientific discoveries into tangible pharmaceutical products.
Structured under a Hub-and-Spoke model, the National Center Foundation for Gene Therapy and Drugs Based on RNA Technology serves as the central Hub, facilitating coordination and resource allocation across 10 Spokes. The Hub functions as the single point of contact, managing and distributing funds to support research programs, while the Spokes concentrate on translating research outcomes into the development and production of personalized medicines.
The European Union’s National Recovery and Resilience Plan (NRRP Mission 4 – Education and Research) provided the initial funding phase for the National Center, with an allocated investment of €320,036,606.03 to advance Key Enabling Technologies (KETs) in RNA-based therapeutics. Although this initial phase spans 36 months, beginning in November 2022, the Center’s scientific and technological progress is designed to extend well beyond the official reporting period, ensuring the continuity of its mission through new and sustained funding initiatives.
